Galena Biopharma
Galena Biopharma was a biopharmaceutical company focused on developing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care. The company was headquartered in San Ramon, California.
History[edit]
Galena Biopharma was originally founded as RXi Pharmaceuticals Corporation in 2006. The company underwent a name change to Galena Biopharma in 2011 to reflect its new focus on oncology. In 2017, Galena Biopharma merged with Sellas Life Sciences Group, a clinical-stage biopharmaceutical company, and the combined entity continued under the name Sellas Life Sciences.
Products and Pipeline[edit]
Galena Biopharma's product pipeline included several immunotherapy-based treatments aimed at various types of cancer. The company's most notable product candidates included:
- NeuVax (nelipepimut-S): A peptide-based vaccine designed to prevent the recurrence of breast cancer in patients with low to intermediate HER2 expression.
- GALE-301 and GALE-302: Cancer immunotherapy vaccines targeting the folate binding protein, aimed at preventing the recurrence of ovarian and endometrial cancers.
Research and Development[edit]
Galena Biopharma focused on the development of targeted cancer therapies, particularly in the field of immunotherapy. The company's research efforts were centered on harnessing the body's immune system to fight cancer cells, thereby offering a novel approach to cancer treatment.
Corporate Strategy[edit]
The company's strategy involved advancing its clinical pipeline through strategic partnerships and collaborations. Galena Biopharma aimed to leverage its expertise in immunotherapy to develop treatments that could be used in combination with existing cancer therapies to improve patient outcomes.
Merger with Sellas Life Sciences[edit]
In 2017, Galena Biopharma merged with Sellas Life Sciences Group. The merger was intended to create a more robust pipeline of cancer immunotherapies and to enhance the combined company's ability to bring innovative treatments to market. The merged entity continued to focus on the development of targeted cancer therapies.
Related pages[edit]
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
